Vaccine Development

Aug 02, 2007
BioPharm International
By BioPharm International Editors
With the advent of high-resolution mass spectrometers and highly sensitive MS instruments, vaccine characterization has entered a new phase.
Aug 02, 2007
BioPharm International
By BioPharm International Editors
For pandemic vaccine processing, single-use filter cartridges and membrane chromatography technologies could offer significant time- and cost-reduction advantages.
Aug 01, 2007
BioPharm International
By BioPharm International Editors
The mounting threats of pandemic influenza, bioterrorism, and emerging infectious diseases continue to be the focus of research programs and funding initiatives, not only within governmental agencies, but also universities, private research firms, and commercial manufacturing entities. With all of these efforts, however, the question of manufacturing capacity and the ability to respond to pandemic and emerging threats continues to be a major concern.
Jun 21, 2007
BioPharm International
By BioPharm International Editors
The US Food and Drug Administration (FDA, Rockville, MD, www.fda.gov) has issued final recommendations for increasing the supply of safe and effective influenza vaccines for both seasonal and pandemic use.
May 01, 2007
BioPharm International
Fortunately for all of us, not everyone's head is in the sand.
Apr 22, 2007
BioPharm International
By BioPharm International Editors
The FDA's (Rockville, MD, www.fda.gov) first approval in the United States of a vaccine for humans against the H5N1 influenza virus marks an important step forward in protecting the public against a pandemic influenza outbreak.
Apr 01, 2007
BioPharm International
By BioPharm International Editors
Frequently asked questions on implementing and using single-use technologies
Apr 01, 2007
BioPharm International
The Chinese vaccine market competition is now transferring from the former price-competition model to a technology- competition model.
Jul 01, 2006
BioPharm International
The approvals of two groundbreaking vaccines in the last month is encouraging news. Vaccines have long been undervalued because they haven't been as profitable as other pharmaceuticals. So it's good to see them getting deserved attention that goes beyond fears of flu outbreaks.
Jun 27, 2006
BioPharm Bulletin
The transdermal delivery of biologics-as well as of conventional drugs-is growing in popularity because the technique offers numerous advantages.
native1_300x100
lorem ipsum